Meagan Parrish from Pharma Voice - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting		Spravato is just the beginning in a new wave of depression meds - 6 days ago CEO with type 1 diabetes works to deliver ‘world’s first’ functional cure - 12 days ago Pharma takes aim at a wily foe — the Epstein-Barr virus - 13 days ago A sickle cell cure exists. But patients need more than just gene therapy. - 17 days ago 2024 PharmaVoice 100s: Rare Disease Warriors - 20 days ago On the front lines of the superbug war, new treatments can’t arrive soon enough - 21 days ago J&J’s comeback kid Spravato heads for blockbuster status - 24 days ago Dengue is spreading and Sanofi is pulling the U.S. market’s only vaccine. What’s next? - 26 days ago 2024 PharmaVoice 100s: Patient Champions - 27 days ago Clinical staff that feel like ‘tech support’ — and other issues a CRO exec contends with - about 1 month ago 2024 PharmaVoice 100s: Trailblazers - about 1 month ago Want to launch a blockbuster? An AstraZeneca exec breaks it down. - about 1 month ago 2024 PharmaVoice 100s: Standout Leaders - about 1 month ago BMS’ next act for Cobenfy — and other highs and lows in Alzheimer’s - about 1 month ago An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped? - about 1 month ago California is a life sciences leader. Joe Panetta has been one of its most vocal advocates. - about 2 months ago After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum? - about 2 months ago Who’s winning in biotech’s tight market? - 2 months ago Why pharma should redefine ‘women’s health’ - 2 months ago What 3 layoff stories reveal about pharma’s troubles - 2 months ago Pharma’s ‘it’ therapy — a new drug class gaining steam - 2 months ago Is anyone taking the world’s priciest drugs? - 3 months ago What pharma has learned from AI - 4 months ago Neuro drugs are still faltering, despite rising investment - 4 months ago Bird flu puts BARDA back in the spotlight - 4 months ago Amylyx’s CEOs on their ALS setback and quest to revamp the pipeline - 4 months ago Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders - 4 months ago Up-and-comers look for an edge in the bustling ADC field - 5 months ago Pfizer’s Paxlovid flunks long COVID study as researchers uncover the condition’s deep toll - 5 months ago Despite adcomm rejection, Lykos CEO sees future for MDMA drug - 5 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 5 months ago Where competition is heating up in pharma - 6 months ago After Vyvanse patent loss, Takeda’s neuroscience division looks to enter a new era - 6 months ago Takeover target? Activist investor believes Novavax tech would be in ‘better hands’ with Big Pharma - 7 months ago As BMS announces major cuts, its Karuna deal looks poised to drive growth - 7 months ago 3 big recent trial flops - 7 months ago Viral return: 3 U.S. cases concerning experts - 8 months ago The pharma ‘fixer’ now helping Gates MRI’s tuberculosis battle - 8 months ago GSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that. - 8 months ago After Amylyx drug failure, what’s next for ALS? - 8 months ago As colorectal deaths rise among younger people, a screening tool could help pinpoint more patients - 8 months ago Neurvati touts fresh, ‘synergistic’ investment model in neuroscience R&D - 8 months ago Into the unknown: Tarsus’ CEO on its launch strategies in a new disease category - 8 months ago Behind a big-name rare disease biotech, an exec draws from personal experience - 9 months ago Astellas’ science chief on the leap into new technologies - 9 months ago Could Novo, Lilly become first trillion-dollar healthcare companies? - 10 months ago ‘1 plus 1 equals 3’ — the co-CEO model in pharma - 10 months ago The biggest questions hanging over pharma in 2024 - 10 months ago Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention - 10 months ago Pharma execs sound off on trends and policies they’re tracking in 2024 - 10 months ago